Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog

Journal of Nuclear Medicine

Volumn 38, Issue 11, 1997, Pages 1737-1741

  Villemagne, Victor L ^b   Horti, Andrew ^b   Scheffel, Ursula ^b   Ravert, Hayden T ^b   Finley, Paige ^b   Clough, David J ^b   London, Edythe D ^b   Wagner Jr , Henry N ^b   Dannals, Robert F ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NONE

Author keywords

Brain; Epibatidine; Nicotinic receptors; Nonhuman primate; PET

Indexed keywords

2 (2 FLUORO 5 PYRIDYL) 7 AZABICYCLO[2.2.1]HEPTANE; CYSTINE; EPIBATIDINE; FLUORINE 18; NICOTINIC RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; BABOON; BRAIN; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; FEASIBILITY STUDIES; FLUORINE RADIOISOTOPES; HUMANS; MALE; PAPIO; PYRIDINES; RADIOPHARMACEUTICALS; RATS; RECEPTORS, NICOTINIC; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030720025     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Decker MW, Brioni JD, Bannon AW, Arneric SP. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci 1995;56:545-570.
2. Flicker DRL, Watkins DL, Fisher SK, Bartus RT. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to cerebral cortex in rat. Pharmacol. Biochem and Behav 1983;18:973-981.
3. Irle E, Markowitsch HJ. Basal forebrain-lesioned monkeys are severely impaired in tasks of association and recognition memory. Ann Neurol 1985;14:1025-1032.
4. Levin ED, Rose JE. Acute and chronic nicotinic interactions with dopamine systems and working memory performance. Ann N Y Acad Sci 1995;757:245-252.
5. Pert A. Cholinergic and catecholaminergic modulation of nociceptive reactions. Interactions with opiates. In: Akil H, Lewis JW, eds. Pain and headache, neurotransmitters and pain control. Basel. Switzerland: S Karger; 1987:1-63
6. Benowitz NL, Porchet H, Jacob P III. Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations. Prog Brain Res 1989;79:279-287.
7. Henningfield JE, Woodson PP. Dose-related actions of nicotine on behavior and physiology: review and implications for replacement therapy for nicotine dependence. J Subst Abuse 1989;1:301-317.
8. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion RJ. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. Neurochem 1988;50:1914-1923.
9. Kellar KJ, Whitehouse PJ, Martino-Barrows AM, Marcus K, Price DL. Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex. Brain Res 1987;436:62-68.
10. London ED, Ball MJ, Waller SB. Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia. Neurochem Res 1989;14:745-750.
11. 3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 1986;72:115-119.
12. Palacios JM, Mengod G, Vilaro MT, et al. Cholinergic receptors in the rat and human brain: microscopic visualization. Prog Brain Res 1990;84:243-253.
13. Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL, Kellar KJ. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986;371: 146-151.
14. 3H]-nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology 1988;38:720-723.
15. Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, Kellar KJ. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 1988;45:722-724.
16. Nef P, Oneyser C, Alliod C, Couturier S, Ballivet M. Genes expressed in the brain define three distinct neuronal nicotinic acetylcholine receptors. EMBO J 1988;7:595-601.
17. 3H]cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 1991;39:9-12.
18. 3H]nicotine and [125I]-alpha-bungarotoxin. J Neuroscience 1985;5:1307-1315.
19. 125I-neuronal bungarotoxin. J Neurosci 1991;11:287-297.
20. Flores CM, Rogers SW, Pabreza LA, Wolfe B, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 1992;41:31-37.
21. Nybäck H, Nordberg A, Långström B, et al. Attempts to visualize nicotinic receptors in the brain of monkey and man by positron emission tomography. Prog Brain Res 1989;79:313-319.
22. 11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995;9:21-27.
23. Badio B, Daly JW. Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol 1994;45:563-569.
24. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol Pharmacol 1995;48:280-287.
25. 3H-epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. J Pharmacol Exp Ther 1995;275:1030-1034.
26. 3H]epibatidine. Eur J Pharm 1995;278:R1-R2.
27. Scheffel U, Taylor GF, Kepler JA, Carroll FI, Kuhar MJ. In vivo labeling of neuronal nicotinic acetylcholine receptors with radiolabeled isomers of norchloroepibatidine. NeuroReport 1995;6:2483-2488.
28. 18F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane. J Labell Comp Radiopharm 1996; 38:355-366.
29. Riche D, Hantraye P, Guibert B, Naquet R, Loc'h C, Maziere B, Maziere M. Anatomical atlas of the baboon's brain in the orbito-meatal plane used in experimental positron emission tomography. Brain Res Bull 1988;20:283-301.
30. 3H]nicotine binding sites in the rat brain. Neurosci Lett 1985;53:179-184.
31. Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 1992;31:103-111.
32. Horti AG, Ravert HT, Mathews WB, Musachio JL, Kimes A, London ED, Dannals RF. Synthesis of high specific activity carbon-11 N-methylated analogs of epibatidine for imaging nAChRs [Abstract]. J Nucl Med 1996;37:192P.
33. Cimino M, Marini P, Fornasari D, Cattabeni F, Clementi F. Distribution of nicotinic receptors in cynomologus monkey brain and ganglia: localization of alpha 3 subunit mRNA, alpha-bungarotoxin and nicotine binding sites. Neuroscience 1992;51:77-86.
34. Pauly JR, Marks MJ, Gross SD, Collins AC. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. J Pharmacol Exp Ther 1991;258:1127-1136.
35. Sullivan JP, Decker MW, Brioni JD, et al. (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1994;271:624-631.
36. McKay J, Lindstrom J, Loring RH. Determination of nicotinic receptor subtypes in chick retina using monoclonal antibodies and 3H-epibatidine. Med Chem Res 1994; 4:528-537.
37. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740-747.
38. Huang SC, Barrio JR, Phelps ME. Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. J Cereb Blood Flow Metab 1987;7:214-229.
39. Wong DF, Gjedde A, Wagner HN Jr. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metab 1986;6: 137-146.
40. Wong DF, Gjedde A, Wagner HN Jr, Dannals RF, Douglass KH, Links JM, Kuhar MJ. Quantification of neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity. J Cereb Blood Flow Metab 1986;6:147-153.
41. Gjedde A. High-and low-affinity transport of D-glucose from blood to brain. J Neurochem 1981;36:1463-1471.
42. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants for multiple time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.